SAB Biotherapeutics (SABS) Projected to Post Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $0.12 million for the quarter.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $1.62 on Wednesday. SAB Biotherapeutics has a 12 month low of $1.45 and a 12 month high of $5.01. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average is $2.15 and its two-hundred day moving average is $2.86.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.